In recent quarters, expiring patents in the product lines of the major pharmaceutical companies has become a hot topic. Over the next five years drug companies are expected to lose several patents. In order to compensate for expiring drug patents drug companies have been focusing on mergers and acquisitions in order to shore up their patent lines. Biotech firms in particular have been a beneficiary of this drive to sign agreements with smaller companies.
Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.